Kezar Life Sciences, Inc. financial data

Symbol
KZR on Nasdaq
Industry
Pharmaceutical Preparations
Location
4000 Shoreline Court, Suite 300, South San Francisco, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.16K % -49%
Debt-to-equity 17.5 % +58.8%
Return On Equity -54.5 % -71.3%
Return On Assets -46.4 % -61.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 73M shares +0.37%
Common Stock, Shares, Outstanding 72.9M shares +0.49%
Entity Public Float 173M USD -68.6%
Common Stock, Value, Issued 73K USD 0%
Weighted Average Number of Shares Outstanding, Basic 72.8M shares +0.53%
Weighted Average Number of Shares Outstanding, Diluted 72.8M shares +0.53%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 7M USD
Research and Development Expense 79.9M USD +17.4%
General and Administrative Expense 26.7M USD +20.1%
Operating Income (Loss) -107M USD -18.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -98.6M USD -19.4%
Earnings Per Share, Basic -1.35 USD/shares -17.4%
Earnings Per Share, Diluted -1.35 USD/shares -17.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 28.3M USD +0.59%
Marketable Securities, Current 136M USD -34.8%
Accounts Receivable, after Allowance for Credit Loss, Current 7M USD
Other Assets, Current 935K USD +14.3%
Assets, Current 168M USD -31.2%
Property, Plant and Equipment, Net 3.39M USD -27.3%
Operating Lease, Right-of-Use Asset 2.39M USD -72.3%
Other Assets, Noncurrent 6.52M USD -0.61%
Assets 180M USD -31.7%
Accounts Payable, Current 2.26M USD -9.19%
Employee-related Liabilities, Current 1.8M USD -6.44%
Accrued Liabilities, Current 9.36M USD +10.6%
Liabilities, Current 17.5M USD +27.4%
Operating Lease, Liability, Noncurrent 4.15M USD -44%
Liabilities 29.2M USD -6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -385K USD +53.6%
Retained Earnings (Accumulated Deficit) -394M USD -33.4%
Stockholders' Equity Attributable to Parent 151M USD -35.1%
Liabilities and Equity 180M USD -31.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.9M USD -9.6%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 20.4M USD +24.5%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 72.9M shares +0.49%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.46M USD +43.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 28.3M USD +0.59%
Interest Paid, Excluding Capitalized Interest, Operating Activities 336K USD +8.39%
Deferred Tax Assets, Valuation Allowance 82.5M USD +44.9%
Deferred Tax Assets, Gross 83.8M USD +41.2%
Operating Lease, Liability 7.41M USD -27.3%
Depreciation 1.2M USD +20%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -98.1M USD -19.4%
Lessee, Operating Lease, Liability, to be Paid 8.4M USD -31.3%
Property, Plant and Equipment, Gross 9.33M USD -4.15%
Operating Lease, Liability, Current 3.26M USD +17.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.1M USD +3.49%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.96M USD +3.37%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 987K USD -51.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 347K USD -91.5%
Deferred Tax Assets, Operating Loss Carryforwards 43M USD +13.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.07M USD +61.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 347K USD +23.1%
Operating Lease, Payments 2.78M USD +64.9%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 260K USD +0.39%
Deferred Tax Assets, Net of Valuation Allowance 1.28M USD -45.9%
Share-based Payment Arrangement, Expense 16.4M USD +3.06%
Interest Expense 1.6M USD +12.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%